Martek in Infant Formula Pact

Under the deal, Medici Medical will license Martek's blend of fatty acids.
Author:
Publish date:

Martek Biosciences

(MATK)

will license its proprietary blend of fatty acids to the infant formula company Medici Medical. Under this agreement Medici Medical can use Martek's products, docosahexaenoic acid (DHA) and arachidonic acid (ARA) in infant formula sold in Israel.

Martek's DHA and ARA is the only source of these nutrients that the FDA has cleared for use in U.S infant formula, the company said. It is currently being sold by its licensees in supplemented formulas in more than 60 countries around the world.

Henry Linsert, Jr., CEO of Martek Biosciences, said, "The Medici Medical agreement is yet another example of how formula manufacturers are recognizing the benefits of adding Martek's DHA and ARA to formula, both for their business and the infants they serve."

This story was created through a joint venture between TheStreet.com and IRIS.